Aclaris Therapeutics (ACRS) Assets Average: 2017-2025
Historic Assets Average for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $182.3 million.
- Aclaris Therapeutics' Assets Average rose 6.18% to $182.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.3 million, marking a year-over-year increase of 6.18%. This contributed to the annual value of $208.9 million for FY2024, which is 7.58% down from last year.
- Per Aclaris Therapeutics' latest filing, its Assets Average stood at $182.3 million for Q3 2025, which was down 5.83% from $193.6 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Assets Average ranged from a high of $275.8 million in Q3 2021 and a low of $116.1 million during Q1 2021.
- Moreover, its 3-year median value for Assets Average was $201.4 million (2024), whereas its average is $201.9 million.
- Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 260.73% in 2021, then declined by 27.98% in 2024.
- Over the past 5 years, Aclaris Therapeutics' Assets Average (Quarterly) stood at $257.4 million in 2021, then climbed by 1.46% to $261.1 million in 2022, then declined by 20.39% to $207.9 million in 2023, then declined by 3.14% to $201.4 million in 2024, then grew by 6.18% to $182.3 million in 2025.
- Its Assets Average was $182.3 million in Q3 2025, compared to $193.6 million in Q2 2025 and $209.2 million in Q1 2025.